scholarly journals The beneficial effect of Escalated‐R‐CHOP‐21 for the treatment of diffuse large B‐cell lymphoma in elderly male patients: A propensity‐matched cohort study

2021 ◽  
Author(s):  
Hai‐Xia He ◽  
Yan Gao ◽  
Bing Bai ◽  
Xiao‐Xiao Wang ◽  
Ji‐Bin Li ◽  
...  
Keyword(s):  
Cohort Study ◽  
Beneficial Effect ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Matched Cohort ◽  
Elderly Male ◽  
Large B Cell Lymphoma ◽  
Male Patients ◽  
Large B Cell

scholarly journals B-cell Function Gene Mutations in Diffuse Large B-cell Lymphoma: A Retrospective Cohort Study

EBioMedicine ◽  
2017 ◽  
Vol 16 ◽  
pp. 106-114 ◽  
Author(s):  
Peng-Peng Xu ◽  
Hui-Juan Zhong ◽  
Yao-Hui Huang ◽  
Xiao-Dong Gao ◽  
Xia Zhao ◽  
...  
Keyword(s):  
Cohort Study ◽  
B Cell ◽  
Retrospective Cohort ◽  
Cell Function ◽  
Cell Lymphoma ◽  
Gene Mutations ◽  
B Cell Lymphoma ◽  
B Cell Function ◽  
Large B Cell Lymphoma ◽  
Large B Cell

scholarly journals Impaired Immune Health in Survivors of Diffuse Large B-Cell Lymphoma

2020 ◽  
Vol 38 (15) ◽  
pp. 1664-1675 ◽  
Author(s):  
Tanaya Shree ◽  
Qian Li ◽  
Sally L. Glaser ◽  
Ann Brunson ◽  
Holden T. Maecker ◽  
...  
Keyword(s):  
Cohort Study ◽  
B Cell ◽  
Cancer Diagnosis ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Immune Deficiencies ◽  
Immune Health ◽  
After Cancer ◽  
Large B Cell

PURPOSE Therapeutic advances for diffuse large B-cell lymphoma (DLBCL) have led to an increasing number of survivors. Both DLBCL and its treatments perturb the immune system, yet little is known about immune health during extended survivorship. METHODS In this retrospective cohort study, we compared 21,690 survivors of DLBCL from the California Cancer Registry (CCR) to survivors of breast, prostate, head and neck, and melanoma cancers. We linked their CCR records to a statewide database documenting hospital, emergency room, and ambulatory surgery visits and investigated the incidence of autoimmune conditions, immune deficiencies, and infections 1-10 years after cancer diagnosis. RESULTS We found elevated incidence rate ratios (IRRs) for many immune-related conditions in survivors of DLBCL compared with other cancer survivors, including significantly and consistently elevated IRRs for viral and fungal pneumonias (up to 10.8-fold), meningitis (up to 5.3-fold), as well as humoral deficiency (up to 17.6-fold) and autoimmune cytopenias (up to 12-fold). IRRs for most conditions remained high even in the late survivorship period (5-10 years after cancer diagnosis). The elevated risks could not be explained by exposure to chemotherapy, stem-cell transplantation, or rituximab, except for IRRs for humoral deficiency, which were consistently higher after the incorporation of rituximab into DLBCL treatments. CONCLUSION To our knowledge, this is the largest cohort study with extended follow-up to demonstrate impaired immune health in survivors of DLBCL. The observed persistent, elevated risks for autoimmune diseases, immune deficiencies, and infectious conditions may reflect persistent immune dysregulation caused by lymphoma or treatment and may lead to excess morbidity and mortality during survivorship. Improved understanding of these risks could meaningfully improve long-term care of patients with DLBCL.

Sign in / Sign up

Export Citation Format

Share Document